{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:53:49Z","timestamp":1789016029228,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Swiss Cancer League","award":["SCL #38-167"],"award-info":[{"award-number":["SCL #38-167"]}]}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejim.2018.05.026","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T14:34:58Z","timestamp":1544106898000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Myelodysplastic syndromes and acute myeloid leukemias in the elderly"],"prefix":"10.1016","volume":"58","author":[{"given":"Beatrice U.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.05.026_bb0005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2016.54","article-title":"Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia","volume":"30","author":"B\u00fcchner","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.026_bb0010","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/leu.2016.25","article-title":"Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia","volume":"30","author":"Krug","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.026_bb0015","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2005.06.090","article-title":"Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study","volume":"23","author":"Farag","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0025","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0030","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are the major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from the AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-09-307264","article-title":"Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities","volume":"118","author":"Perrot","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"AMLCG study group, Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome","volume":"27","author":"Schnittger","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.026_bb0050","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 mutations improve the new european LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study","volume":"29","author":"Metzeler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0055","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.026_bb0060","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0065","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a cancer and leukemia group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0070","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","article-title":"FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study","volume":"116","author":"Whitman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.13873","article-title":"The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia","volume":"172","author":"Dickson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0085","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","article-title":"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia","volume":"30","author":"Marcucci","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-016-1942-1","article-title":"TP53 mutations in older adults with acute myeloid leukemia","volume":"103","author":"Yanada","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0095","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0100","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.026_bb0105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2018.05.026_bb0110","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.026_bb0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Gen"},{"key":"10.1016\/j.ejim.2018.05.026_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0125","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0130","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejim.2018.05.026_bb0135","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.05.026_bb0140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.V128.22.589.589","article-title":"Results of the randomized phase II study decider (AMLSG 14-09) comparing decitabine (DAC) with or without valproic acid (VPA) and with or without all-trans retinoic acid (ATRA) add-on in newly diagnosed elderly non-fit AML patients","volume":"128","author":"L\u00fcbbert","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0155","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0160","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/13543784.2016.1216971","article-title":"Panobinostat for the treatment of acute myelogenous leukemia","volume":"25","author":"Morabito","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejim.2018.05.026_bb0165","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2018.05.026_bb0170","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0175","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0180","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0185","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/blood.V126.23.532.532","article-title":"Impact of comorbidities at diagnosis of acute myeloid leukemia on one-year mortality","volume":"126","author":"Sorror","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0190","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood.V128.22.216.216","article-title":"Intensive versus non-intensive induction therapy for patients (pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic models","volume":"128","author":"Sorror","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0195","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"UK NCRI AML study group. A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.026_bb0200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/ejh.12757","article-title":"The FLAG chemotherapy regimen is an alternative to anthracycline based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease","volume":"97","author":"Saini","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.026_bb0210","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomized controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.026_bb0220","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia-updated results of the Italian-German APL0406 trial on the extended final series","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2016.12.001","article-title":"Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65\u202fyears","volume":"53","author":"Heini","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejim.2018.05.026_bb0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0235","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0240","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.05.026_bb0245","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.05.026_bb0250","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2013.297","article-title":"Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG","volume":"28","author":"Fiegl","year":"2014","journal-title":"Leukemia"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051830222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051830222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:12:19Z","timestamp":1605571939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051830222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"alternative-id":["S095362051830222X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.05.026","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic syndromes and acute myeloid leukemias in the elderly","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}